Pelargonium sidoides preparation EPs 7630 in COPD: health-related quality-of-life and other patient-reported outcomes in adults receiving add-on therapy

References

• Geldmacher H, Biller H, Herbst A, et al. Die Prävalenz der chronisch obstruktiven Lungenerkrankung (COPD) in Deutschland. [The prevalence of chronic obstructive pulmonary disease (COPD) in Germany. Results of the BOLD study]. Dtsch Med Wochenschr 2008;133:2609-14 [German]
   PubMedGoogle Scholar
• Gibson GJ, Loddenkemper R, Lundbäck B, et al. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J 2013;42:559-63
   PubMed Web of Science ®Google Scholar
• Brunton S, Carmichael BP, Colgan R, et al. Acute exacerbation of chronic bronchitis: a primary care consensus guideline. Am J Manag Care 2004;10:689-96
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2009. Executive Summary. Available at: https://hmsa.com/portal/provider/GOLD_Report_08_WM1.pdf. [Last accessed 10 January 2018]
   Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al., on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-68
   PubMed Web of Science ®Google Scholar
• Gillissen A, Buhl R, Kardos P, et al. Studienendpunkte bei der chronisch-obstruktiven Lungenerkrankung (COPD): “Minimal clinically important difference” [Trial end-point in chronic obstructive pulmonary disease (COPD): minimal clinically important difference]. Pneumologie 2008;62:149-57 [German]
   PubMedGoogle Scholar
• Lin XJ, Lin IM, Fan SY. Methodological issues in measuring health-related quality of life. Tzu Chi Med J 2013;25:8-12
   Google Scholar
• Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, June, 19–22, 1946
   Google Scholar
• Weldring T, Smith SMS. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights 2013;6:61-8
   PubMedGoogle Scholar
• Bullinger M. Das Konzept der Lebensqualität in der Medizin - Entwicklung und heutiger Stellenwert [The concept of quality of life in medicine – development and current importance]. Z Evid Fortbild Qual Gesundh wesen 2014;108:97-103 [German]
   PubMedGoogle Scholar
• Bullinger M, Siegrist J, Ravens-Sieberer U, editors. Jahrbuch der Medizinischen Psychologie, Band 18, Lebensqualitätsforschung aus medizinpsychologischer und -soziologischer Perspektive [Quality of life research from a medical-psychological and sociological perspective]. Göttingen: Hogrefe; 2000 [German]
   Google Scholar
• Marks GB, Dunn SM, Wollcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol 1992;45:461-72
   PubMed Web of Science ®Google Scholar
• Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:680-5
   PubMed Web of Science ®Google Scholar
• Schöffski O, Graf von der Schulenburg JM, editors. Gesundheitsökonomische Evaluationen [Health-economic evaluations]. Heidelberg: Springer; 2007 [German]
   Google Scholar
• Rutishauser C, Sawyer SM, Bowes G. Quality of life assessment in children and adolescents with asthma. Eur Respir J 1998;12:486-94
   PubMed Web of Science ®Google Scholar
• Schmier JK, Halpern MT, Higashi MK, et al. The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature review. Qual Life Res 2005;14:329-47
   PubMed Web of Science ®Google Scholar
• Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations – comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010;8:39
   PubMed Web of Science ®Google Scholar
• Matthys H, Pliskevich DA, Bondarchuk OM, et al. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD. Respir Med 2013;107:691-701
   PubMed Web of Science ®Google Scholar
• Matthys H, Malek FA. Antibiotic use in patients with COPD receiving EPs 7630 as an add-on treatment. Atemwegs- und Lungenkrankheiten 2015;1:27-34
   Google Scholar
• Matthys H, Lehmacher W, Zimmermann A, et al. EPs 7630 in acute respiratory tract infections – a systematic review and meta-analysis of randomized clinical trials. J Lung Pulm Respir Res 2016;3(1):00068
   Google Scholar
• Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis. Phytomedicine 2008;15:378-85
   PubMed Web of Science ®Google Scholar
• Agbabiaka TB, Guo R, Ernst E. Erratum to “Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis” [Phytomedicine 15 (2008) 378–85]. Phytomedicine 2009;16:798-9
   Web of Science ®Google Scholar
• Timmer A, Günther J, Motschall E, et al. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013;10:CD006323
   PubMed Web of Science ®Google Scholar
• Matthys H, Köhler S, Kamin W. Safety and tolerability of EPs 7630 in clinical trials. Adv Pharmacoepidemiol Drug Saf 2013;2:142
   Google Scholar
• Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides DC. Phytother Res 2001;15:122-6
   PubMed Web of Science ®Google Scholar
• Kolodziej H. Fascinating metabolic pools of Pelargonium sidoides and Pelargonium reniforme, traditional and phytomedicinal sources of the herbal medicine Umckaloabo®. Phytomedicine 2007;14(Suppl6):9-17
   Google Scholar
• Kolodziej H, Kayser O, Radtke OA, et al. Pharmacological profile of extracts of Pelargonium sidoides and their constituents. Phytomedicine 2003;10(Suppl4):18-24
   Web of Science ®Google Scholar
• Kolodziej H, Kiderlen AF. In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs® 7630. Phytomedicine 2007;14(Suppl4):18-26
   Google Scholar
• Witte K, Koch E, Volk HD, et al. The Pelargonium sidoides extract EPs 7630 drives the innate immune defense by activating selected MAP kinase pathways in human monocytes. PLoS One 2015;10:e0138075
   PubMed Web of Science ®Google Scholar
• Conrad A, Hansmann C, Engels I, et al. Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro. Phytomedicine 2007;14(Suppl6):46-51
   Google Scholar
• Conrad A, Jung I, Tioua D, et al. Extract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro. Phytomedicine 2007;14(Suppl6):52-9
   Google Scholar
• Rezaizadehnajafi L, Wink M. EPs7630® from Pelargonium sidoides increases stress resistance in Caenorhabditis elegans probably via the DAF-16/FOXO pathway. Phytomedicine 2014;21:547-50
   PubMed Web of Science ®Google Scholar
• Michaelis M, Doerr HW, Cinatl J Jr. Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine 2011;18:384-6
   PubMed Web of Science ®Google Scholar
• Neugebauer P, Mickenhagen A, Siefer O, et al. A new approach to pharmacological effects on ciliary beat frequency in cell cultures—exemplary measurements under Pelargonium sidoides extract (EPs 7630). Phytomedicine 2005;12(1–2):46-51
   PubMed Web of Science ®Google Scholar
• Bao Y, Gao Y, Koch E, et al. Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis. Phytomedicine 2015;22:504-9
   PubMed Web of Science ®Google Scholar
• Matthys H, Lizogub VG, Funk P, et al. Pelargonium sidoides bei akuter Bronchitis – Gesundheitsbezogene Lebensqualität und Therapiebeurteilung aus Patientensicht unter Behandlung mit EPs 7630. [Pelargonium sidoides in acute bronchitis – Health-related quality of life and patient-reported outcome in adults receiving EPs 7630 treatment]. Wien Med Wochenschr 2010;160:564-570 [German]
   PubMedGoogle Scholar
• Kind P. Chapter 22. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2. Philadelphia: Lippincott-Raven Publishers; 1996. pp. 191-201
   Google Scholar
• Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St. George’s Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7
   PubMed Web of Science ®Google Scholar
• Steinsbekk A, Biolchini J, Heger M, et al. Data collection in homeopathic practice - a proposal for an international standard. HomInt R&D Newsletter 1999;2:3-23
   Google Scholar
• Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD 2005;2:75-9
   PubMedGoogle Scholar
• Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. Curr Med Res Opin 2013;29:1383-90
   PubMedGoogle Scholar